Expert Interview
A Second Viewpoint: Investigating the Phase 3 Vivacity-MG3 clinical trial data on Nipocalimab in patients with myasthenia gravis.
Ticker(s): JNJInstitution: University of Buffalo
- Professor and immediate past Chairman of the Department of Neurology at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, State University of New York (SUNY).
- Currently manages 74 patients for myasthenia gravis.
- Research focus includes neuromuscular disorders, particularly on myasthenia gravis and peripheral neuropathies and has authored or coauthored over 155 papers on neuromuscular disorders.
Could you provide some details about your professional background and clinical practice, including how many myasthenia gravis patients you manage and your treatment approach?
Can you discuss the treatment options for Myasthenia Gravis, including your approach to conventional therapies versus newer agents like Fc receptor antagonists?
What are your thoughts on the advantages, potential use, and market share of different drugs for Myasthenia Gravis, including RYSTIGGO, VYVGART, and Nipocalimab?
Added By: catalin_adminHow would you rate your excitement level about Nipocalimab compared to other emerging treatments, and what other future treatment approaches for Myasthenia Gravis are you excited about?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
